Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 19/20 | 0.84 |
| ▸ | PTGDR | Q13258 | 12/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 6/20 | 0.84 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16558828 | 0.91 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RHTR6CYP2C9 | |
| SCHEMBL16558832 | 0.91 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RHTR6CYP2C9 | |
| SCHEMBL19799334 | 0.91 | PTGDR2 (0.85) | PTGDR2PTGDRTBXA2RHTR6CYP2C9 | |
| SCHEMBL26978682 | 0.90 | PTGDR2 (0.80) | PTGDR2PTGDRTBXA2RHTR6CYP2C9 | |
| Trifluoromethanesulfonic Acid SCHEMBL27124564 | 0.84 | PTGDR2 (0.74) | PTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL7409341 | 0.84 | PTGDR2 (0.72) | PTGDR2PTGDRTBXA2RHTR6 | |
| Hydrochloric Acid SCHEMBL7408565 | 0.83 | PTGDR2 (0.71) | PTGDR2PTGDRTBXA2RHTR6 | |
| SCHEMBL16558831 | 0.82 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RHTR6CYP2C9 | |
| SCHEMBL23616417 | 0.81 | PTGDR2 (0.81) | PTGDR2PTGDRTBXA2RHTR6CYP2C9 | |
| SCHEMBL1427760 | 0.81 | PTGDR2 (0.81) | PTGDR2PTGDRTBXA2RCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330062-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | INST NAT SANTE RECH MED (FR) | 2023-10-19 | — | — | US | disclosed |
| US-20180021302-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021302-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | PTGDR, PTGDR2, PTGIR | PTGDR2 2/4885PTGDR 1/4885TBXA2R 10/4885 |
| US-20230330062-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | PTGDR2, PTGDR, PTGIR | PTGDR2 1/4885PTGDR 2/4885TBXA2R 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.